Literature DB >> 7621473

Endocrine control of prostate cancer.

G Wilding1.   

Abstract

Steroid hormones play an important part in prostate biology. Androgens are crucial for the normal development of the prostate gland and in maintaining its functional state in the adult. It seems that the prolonged presence of androgens might also be an important factor in the development of prostate cancer. In addition, androgens and oestrogens appear to play a part in the development of benign prostatic hypertrophy, although the exact nature of their role has not been clearly defined. Stimulation of prostate cancer growth by androgens is well established with androgen withdrawal therapy being the most effective therapy in men with prostate cancer. Additive steroid therapy of metastatic prostate cancer with oestrogens or progestogens has also proved effective. The effects of androgens on prostate cancer cell growth might be mediated through modulation of growth factor expression and alteration of growth factor receptor levels. Androgen response can be modulated by the expression of mutated oncogenes such as ras. Androgen independence can occur through a loss of AR expression or mutation of the AR; however, the patterns of AR expression in normal prostatic tissue from development to adulthood and in cancer are now just beginning to be described. Other steroids, such as the retinoids, show promise as preventive agents, possibly through the modulation of growth factors. Vitamin D compounds modulate prostate cancer cell growth, but their role in prevention and therapy is unclear.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7621473

Source DB:  PubMed          Journal:  Cancer Surv        ISSN: 0261-2429


  13 in total

1.  Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells.

Authors:  Farideh Mehraein-Ghomi; Hirak S Basu; Dawn R Church; F Michael Hoffmann; George Wilding
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

2.  Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy.

Authors:  S Slater; R T Oliver
Journal:  Drugs Aging       Date:  2000-12       Impact factor: 3.923

3.  Resveratrol-induced gene expression profiles in human prostate cancer cells.

Authors:  Sunita B Jones; Samuel E DePrimo; Michael L Whitfield; James D Brooks
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-03       Impact factor: 4.254

Review 4.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 5.  Androgen receptor gene and hormonal therapy failure of prostate cancer.

Authors:  P Koivisto; M Kolmer; T Visakorpi; O P Kallioniemi
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

6.  A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model.

Authors:  Hirak S Basu; Todd A Thompson; Dawn R Church; Cynthia C Clower; Farideh Mehraein-Ghomi; Corey A Amlong; Christopher T Martin; Patrick M Woster; Mary J Lindstrom; George Wilding
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

Review 7.  Oxidative stress in prostate cancer.

Authors:  Lakshmipathi Khandrika; Binod Kumar; Sweaty Koul; Paul Maroni; Hari K Koul
Journal:  Cancer Lett       Date:  2009-01-30       Impact factor: 8.679

8.  A multifunctional androgen receptor screening assay using the high-throughput Hypercyt flow cytometry system.

Authors:  Megan K Dennis; Harmony J C Bowles; Debra A MacKenzie; Scott W Burchiel; Bruce S Edwards; Larry A Sklar; Eric R Prossnitz; Todd A Thompson
Journal:  Cytometry A       Date:  2008-05       Impact factor: 4.355

Review 9.  Anti-oxidants from green tea and pomegranate for chemoprevention of prostate cancer.

Authors:  Vaqar Mustafa Adhami; Hasan Mukhtar
Journal:  Mol Biotechnol       Date:  2007-09       Impact factor: 2.695

10.  Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation.

Authors:  Samantha R Lewis; Curtis J Hedman; Toni Ziegler; William A Ricke; Joan S Jorgensen
Journal:  Endocrinology       Date:  2013-11-21       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.